Bristol Myers Squibb Presents First Clinical Data from Two Phase 3 Studies in the ADEPT Program Evaluating KarXT for Psychosis Associated with Alzheimer’s Disease

Bristol Myers Squibb (BMY) shared preliminary Phase 3 data for KarXT in treating psychosis linked to Alzheimer's. ADEPT-1 showed improvements in hallucination and delusion scores over 12 weeks. ADEPT-3 reported long-term safety and tolerability data over 52 weeks. Both studies observed symptom score improvements and a favorable safety profile.

Original reporting
Published Nov 18, 2026, 2:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 2:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$BMY
Bullish
medium confidence
Mentioned
$BMY
Relevance
7/10
AlphAI data visualization · based on finance.yahoo.com
Decision brief

The 30-second read

$BMYBullishMed
01

Why it matters

The disclosure is the first clinical data from the Phase 3 ADEPT program, showing clinician-observed improvements in hallucinations and delusions and reporting tolerability without new safety signals, but it does not yet reveal efficacy from the blinded treatment periods.

02

Market read

Traders may reassess KarXT’s Phase 3 probability of success based on preliminary symptom improvements and tolerability, while awaiting blinded efficacy and relapse outcomes.

03

What to watch

TEAE and discontinuation rates are not negligible, and the study’s primary endpoint is time to relapse during the blinded withdrawal period, which is not yet reported.

Relevance 7/10Novelty 7/10Timing: today at CTAD conference, with preliminary Phase 3 ADEPT-1 and ADEPT-3 data disclosed

Background

BMY is evaluating KarXT (xanomeline plus trospium) in the Phase 3 ADEPT program for psychosis associated with Alzheimer’s disease, with multiple studies including ADEPT-1 and a long-term ADEPT-3 rollover extension.

Company-level read

Ticker impact

$BMYBullishMedium confidence
Context

Bristol Myers Squibb disclosed first Phase 3 ADEPT program clinical data for KarXT, including 12-week and 52-week open-label symptom improvements and no new safety signals.

Expected impact

Likely modest upward bias as traders price improved probability of efficacy and tolerability, tempered by uncertainty until blinded data.

Evidence & confidence

The article provides new, company-specific clinical readouts with quantified score reductions and safety summaries, but it is explicitly preliminary and based on descriptive analyses from open-label periods.

Market effects

Adds incremental momentum to Alzheimer’s psychosis drug development narratives and may increase attention on CNS/neurology trial readouts.

Limited direct regional spillover; primarily affects US-listed biotech sentiment.

Moderate global relevance as CTAD is an international conference and the ADEPT program is global Phase 3.

Counterpoint

Open-label, descriptive analyses can overstate benefit; without double-blind period results, the market may fade the initial enthusiasm.

Key entities

  • Bristol Myers Squibb

    Sponsor of the ADEPT Phase 3 program evaluating KarXT for psychosis associated with Alzheimer’s disease.

  • KarXT (xanomeline and trospium chloride)

    Investigational oral therapy being studied for Alzheimer’s-associated psychosis; already FDA-approved as Cobenfy for schizophrenia.

  • ADEPT-1

    Phase 3 randomized, double-blind placebo-controlled relapse prevention study with a 12-week open-label lead-in period.

  • ADEPT-3

    Phase 3 52-week open-label extension rollover study assessing long-term safety and tolerability.

  • CTAD Conference

    Clinical Trials on Alzheimer’s Disease conference where the preliminary data were presented.

Related articles

$BMYMed

Bristol Myers Squibb shares preliminary KarXT trial data

Bristol Myers Squibb (BMY) presented preliminary Phase 3 data from its ADEPT trials for KarXT in treating psychosis related to Alzheimer’s disease. The studies showed mean reductions in hallucinations and delusions, with adverse events reported. KarXT is FDA-approved for schizophrenia. No treatments are currently approved for Alzheimer’s-related psychosis.

$MRKMedAI 8/10

AHA 2026: Pharmacists at the Center of Cardiometabolic Care

At AHA 2026, data on new cardiometabolic therapies highlighted pharmacists' growing role. Survodutide (Zealand Pharma, Boehringer Ingelheim) showed cardiovascular safety. Enlicitide (Merck) sustained LDL-C reductions. Stanford's model embedded pharmacists in heart failure care. Orforglipron (Eli Lilly) lowered systolic blood pressure. Pharmacists were noted for their critical roles in titration, adherence, and monitoring.

$BMYHigh

Can BMY Sustain Growth in Its Cardiovascular Franchise?

Bristol Myers Squibb (BMY) is expanding its cardiovascular franchise with label expansions for Camzyos, including pediatric approvals, driving sales growth. Camzyos sales surged 61% YoY to $1.1B in 9 months. Eliquis, a key revenue driver, saw $13.3B in sales, up 21% YoY. BMY faces competition from Cytokinetics (CYTK) and Edgewise Therapeutics (EWTX) in the oHCM market. BMY shares gained 15.5% YTD, trading at 9.52X forward earnings.

$GSKMedAI 8/10

Belantamab Mafodotin Moves Into Lenalidomide-Refractory Myeloma in Updated NCCN Guidelines

The NCCN updated its guidelines to include GSK's belantamab mafodotin (Blenrep) plus bortezomib and dexamethasone as a category 1 recommendation for lenalidomide-refractory multiple myeloma. The update also includes two other belantamab triplets under 'Useful in Certain Circumstances' for patients with 3 or more prior therapies. The changes follow the drug's FDA approval in October 2025 and reflect its efficacy in clinical trials.